Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Conference Call Information
To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time.
Alternatively, you may dial 1-833-693-0540 from
A replay will be available through
Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators as potential treatments for patients with Cushing’s syndrome, ovarian, adrenal and prostate cancer, weight gain caused by the use of antipsychotic medications and liver disease. Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome.
Source: Corcept Therapeutics Incorporated